Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TriSalus Life Sciences (TLSIW) Non Operating Income (2022 - 2025)

Historic Non Operating Income for TriSalus Life Sciences (TLSIW) over the last 4 years, with Q3 2025 value amounting to -$94000.0.

  • TriSalus Life Sciences' Non Operating Income fell 62307.69% to -$94000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$487000.0, marking a year-over-year increase of 845.86%. This contributed to the annual value of -$312000.0 for FY2024, which is 1746.03% up from last year.
  • Latest data reveals that TriSalus Life Sciences reported Non Operating Income of -$94000.0 as of Q3 2025, which was down 62307.69% from -$40000.0 recorded in Q2 2025.
  • TriSalus Life Sciences' 5-year Non Operating Income high stood at $3.5 million for Q1 2022, and its period low was -$349000.0 during Q4 2022.
  • Over the past 4 years, TriSalus Life Sciences' median Non Operating Income value was -$40000.0 (recorded in 2025), while the average stood at $316883.1.
  • Data for TriSalus Life Sciences' Non Operating Income shows a peak YoY increase of 6832.3% (in 2024) and a maximum YoY decrease of 70526.32% (in 2024) over the last 5 years.
  • TriSalus Life Sciences' Non Operating Income (Quarter) stood at -$349000.0 in 2022, then increased by 7.74% to -$322000.0 in 2023, then surged by 68.32% to -$102000.0 in 2024, then rose by 7.84% to -$94000.0 in 2025.
  • Its Non Operating Income stands at -$94000.0 for Q3 2025, versus -$40000.0 for Q2 2025 and -$251000.0 for Q1 2025.